Skip to main content
Caplight Logo









Cell-Easy

Cell-Easy

Private
ToulouseHealthcare & Life Scienceshttps://www.cell-easy.com/

Last Round

Grant

Apr 14, 2026

Total Funding Raised

$18.31M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Cell-Easy is a biotechnology company that operates as a Contract Development and Manufacturing Organization (CDMO) specializing in cell therapy, providing services from process development to GMP production for biotech and pharma companies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Quality Management

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

contract development and manufacturing organizationCDMOcell therapy manufacturingGMP manufacturingcell therapybiotech manufacturingprocess developmentquality controlclinical supplyregulatory supportbioprocessingCMC supportbiotech outsourcingcell banking

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cell-Easy Comparables

Compare Cell-Easy with similar companies based on industry and business-model similarity.

Cell-Easy comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Stemmatters
86%
Cellex Cell Professionals GmbH
82%
Cellistic
82%

Cell-Easy Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantApr 14, 2026
GrantFeb 28, 2022
Series ADec 8, 2020
AngelDec 1, 2019

Key People

Founding team and executive leadership

Alexis Delbaere

Directeur Général Chief Executive Officer

Executive Team

Cell-Easy Investors

Notable investors and investment history

Cell-Easy investors
InvestorRounds
Région OccitanieGrant
M CapitalSeries A
IRDI Soridec GestionSeries A
BpifranceGrant
Mérieux Equity PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 1, 2026

    Open roles increased to 12, 34% of headcount.

  • Jul 27, 2026

    Grew 16% QoQ, from 32 to 37 employees.

Cell-Easy Filings

Explore SEC and related filing metadata, where available.

Cell-Easy filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Cell-Easy's valuation, stock price, and market status.

Is Cell-Easy a public or private company?

Cell-Easy is a private company.

What is the current stock price of Cell-Easy?

Cell-Easy is a private company with no public stock price. No recent secondary market data is available.

How much is Cell-Easy worth (valuation)?

Valuation information for Cell-Easy is not publicly available.

Can I buy Cell-Easy stock?

Cell-Easy shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Cell-Easy's last funding round?

Funding round information for Cell-Easy is not publicly available.

Who are the main investors in Cell-Easy?

Investor information for Cell-Easy is not publicly disclosed.

Will Cell-Easy IPO soon?

No public IPO plans have been announced for Cell-Easy.

How can I track Cell-Easy secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Cell-Easy's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersToulouse
Employee Range33
Year Founded2017
Last FundingApr 14, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?